Alembic Pharmaceuticals Limited (BOM: 533573)
India
· Delayed Price · Currency is INR | Market Cap | 207.40B |
| Revenue (ttm) | 63.57B |
| Net Income (ttm) | 6.47B |
| Shares Out | n/a |
| EPS (ttm) | 32.89 |
| PE Ratio | 32.07 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Jul 15, 2024 |
| Volume | 7,304 |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | 750.30 - 1,296.15 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 4, 2025 |
About Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ... [Read more]
Financial Performance
In 2023, Alembic Pharmaceuticals's revenue was 62.29 billion, an increase of 10.19% compared to the previous year's 56.53 billion. Earnings were 6.16 billion, an increase of 80.07%.
Financial StatementsNews
Alembic Pharmaceuticals completes ANVISA GMP Audit for API-II Facility in Brazil
Alembic Pharmaceuticals has recently informed exchanges that the company has successfully completed the GMP audit conducted by the Brazilian Health Regulatory Agency (ANVISA) for its API-II facility i...
Alembic Pharmaceuticals receives tentative USFDA approval for olopatadine hydrochloride solution
Alembic Pharmaceuticals Limited has secured tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for olopatadine hydrochloride ophthalmic s...
Alembic Pharma shares surged nearly 5% today
Alembic Pharmaceuticals shares surged nearly 5% today – as of 9:35 am the shares were trading 4.33% higher at ₹1,086.95 on NSE. Alembic Pharmaceuticals faced a setback as the United States Food and Dr...
Alembic Pharmaceuticals secures USFDA approval for Ivabradine tablets
Alembic Pharmaceuticals Limited (Alembic) recently informed exchanges that the US Food and Drug Administration (USFDA) has granted Final Approval for its Abbreviated New Drug Application (ANDA) Ivabra...
Alembic Pharmaceuticals gains USFDA final approval for Diltiazem Hydrochloride extended-release capsules
Alembic Pharmaceuticals Limited has announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydro...
Alembic Pharma Q2 FY25 Results: Revenue jumps 3.3% YoY to ₹1,647.98 crore, net profit jumps 12.2% YoY
Alembic Pharmaceuticals reported its financial results for Q2 FY25, showing positive year-over-year (YoY) growth in both revenue and net profit, though quarter-over-quarter (QoQ) figures reflected mod...